Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs.
2/5 보강
OpenAlex 토픽 ·
Monoclonal and Polyclonal Antibodies Research
Immunotherapy and Immune Responses
vaccines and immunoinformatics approaches
Antibody prodrugs provide a strategy to reduce systemic toxicity by masking therapeutic antibodies until activation in specific physiological environments.
APA
Anna Mestre Borras, Hanna Mehari, et al. (2026). Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs.. Protein engineering, design & selection : PEDS. https://doi.org/10.1093/protein/gzag010
MLA
Anna Mestre Borras, et al.. "Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs.." Protein engineering, design & selection : PEDS, 2026.
PMID
41989091 ↗
Abstract 한글 요약
Antibody prodrugs provide a strategy to reduce systemic toxicity by masking therapeutic antibodies until activation in specific physiological environments. Nivolumab, an anti-PD-1 checkpoint inhibitor used in cancer immunotherapy, can cause immune-related adverse events. As a first step toward a prodrug version of nivolumab, we screened an Escherichia coli affibody library using MACS and FACS, identifying affibodies that effectively mask its PD-1-binding regions. Deep sequencing revealed an unexpected enrichment of proline-rich variants, possibly mimicking a PD-1 loop. AlphaFold modeling suggested that these affibodies form interactions with nivolumab despite low alpha-helical content. Biosensor assays confirmed effective masking in a nivolumab prodrug format, with PD-1 binding restored upon proteolytic cleavage. These findings support further exploration of PD-1-mimicking affibodies as masking domains, advancing the development of more selective nivolumab prodrugs with improved safety profiles.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- CRISPR/Cas9 Screening Reveals that UBE2L3 Modulates Autophagic Flux through TSC2 Ubiquitination and Potentiates PD-1 Blockade in Triple-Negative Breast Cancer.
- Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.
- Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system.
- Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study.